Crisis Means Opportunity? Lessons From Chinese API Maker’s Rapid Downfall
With its stock plunging 20% over three trading days, Chinese bulk producer Zhejiang Huahai has been hit hard by a spreading worldwide recall of its big-selling valsartan active ingredient, but the issue has also thrown into relief other underlying issues.
You may also be interested in...
EU Regulators Recall Valsartan Products Produced In China
Stada and Accord are among the companies affected by an EU wide recall of valsartan manufactured by a Chinese supplier.
China Micron Ban Not Cause For Further Health Sector Worry?
China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.
'Being Innovative Not Enough': Multinationals Want Driver‘s Seat In Changing China
Multinational pharma firms are exploring their next growth trajectories in China, where some including AstraZeneca and Roche are deepening their commitment by becoming further integrated into local innovation ecosystems and pursuing deals, while others such as Pfizer are focusing on tackling reimbursement challenges.